Centerpoint Advisors’s Cytokinetics CYTK Stock Holding History

Centerpoint Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-24	Closed	-$1K	–	572
2022 Q4	$1K	Hold	24	–	–	﹤0.01%	433
2022 Q3	$1K	Hold	24	–	–	﹤0.01%	347
2022 Q2	$1K	Hold	24	–	–	﹤0.01%	350
2022 Q1	$1K	Hold	24	–	–	﹤0.01%	355
2021 Q4	$1K	Buy	+24	New	+$926	﹤0.01%	367

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Centerpoint Advisors's CYTK Position: Q1 2023 in Review

Centerpoint Advisors sold out of Cytokinetics (CYTK) in Q1 2023, closing a stake of 24 shares — an estimated $1K sold.

Centerpoint Advisors first reported a position in CYTK in Q4 2021 and held it in 5 quarters. The position peaked at $1K in Q4 2022. 262 funds tracked by Wall St. Rank hold CYTK as of Q1 2023.

Centerpoint Advisors reported no remaining Cytokinetics position as of Q1 2023 after selling out during the quarter.
Centerpoint Advisors sold 24 Cytokinetics shares in Q1 2023, an estimated $1K.
Centerpoint Advisors first reported a position in Cytokinetics in Q4 2021 and held it in 5 quarters.
Centerpoint Advisors's Cytokinetics position peaked at $1K in Q4 2022.
262 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2023.

Based on Centerpoint Advisors's 13F filing for Q1 2023, filed 3 May 2023.